Thymalin
Thymalin is a polypeptide complex derived from the thymus gland of young calves, containing short peptides (2-8 amino acids) that regulate gene expression in immune and hematopoietic cells. Originally developed in the 1970s by Khavinson and Morozov at the Kirov Military Medical Academy in Leningrad, thymalin represents a targeted approach to counteracting age-related immune decline through restoration of thymic function and T-lymphocyte differentiation.
This peptide complex has gained considerable attention in immunology and geriatric medicine for its studied role in restoring immune homeostasis, enhancing hematopoiesis, reducing infection susceptibility, and extending healthspan. Thymalin exhibits unique properties as a multi-peptide complex that regulates immune cell differentiation and maintains bioactivity across various clinical applications, making it distinctive among immunomodulatory peptides with decades of clinical use in Eastern Europe.
Overview
Thymalin contains a heterogeneous mixture of thymic peptides that regulate gene expression in immune and hematopoietic cells. The complex is formulated as a lyophilized injectable solution for parenteral use and demonstrates superior stability and biological activity compared to individual peptide components, with detectability and immune effects persisting for weeks post-administration.
Chemical structure & Properties
- Molecular Formula: Complex mixture of short peptides
- Molecular Weight: approximately 200-1,000 Da for individual peptide components (heterogeneous mixture)
- Sequence: Short peptides (2-8 amino acids) from calf thymus
- Half-life: Variable based on peptide components
- Stability: Stable at refrigerated conditions (2-8°C) in sealed ampoules
Mechanism of Action
Thymalin exerts its therapeutic effects through multiple interconnected molecular pathways:
Areas Investigated in
the Research Literature
Current Clinical Evidence
Safety Profile and Considerations
Regulatory Status and Legal Considerations
Regulatory information current as of 28 August 2026. This is a summary, not legal or medical advice, and status can change.
FDA Status
- Classification: Investigational peptide complex, not approved for therapeutic use
- Approval Status: Not approved for human therapeutic use in the United States
- Development Stage: Approved in Russia, investigational in Western markets
- Regulatory Position: Requires clinical trials for FDA approval pathway
International Status
- Russian Federation: Approved for clinical use as immunomodulatory agent
- Eastern Europe: Widely used in clinical practice
- Western Markets: Available through research channels and compounding pharmacies
Legal Availability
- Commercial Status: Not legally available as prescription medication in the US
- Market Presence: Available through specialized research and compounding sources
- Quality Control: Variable quality and purity verification essential
- Clinical Use: Limited to research settings and experimental protocols in Western countries
Conclusion
What the evidence supports
Thymalin is a thymus-derived peptide preparation studied for immune modulation, primarily in Russian clinical practice and preclinical models. That evidence has not been replicated in independent controlled trials, and there is no standardized dosing or long-term safety data in Western use. Thymalin is not FDA approved for any therapeutic use in the United States. This page summarizes the published research and nothing further.
Thymalin SCIENTIFIC
DATA SUMMARY
About this library
This library is published for education. It summarizes published research on compounds studied in this field. Many have no approved medical use, and several cannot lawfully be compounded in the United States. The presence of a page here does not mean Paragon offers that compound. Nothing on these pages is an offer to treat.
This page is general education about a compound studied in this field. Nothing here is medical advice, a recommendation, or an offer to prescribe or supply. A page appearing in this library does not mean Paragon Sports Medicine offers that compound.
Disclaimer: This information is provided for educational purposes only and does not constitute medical advice. Thymalin is not approved by the FDA for human therapeutic use in the United States. Access may be limited to research protocols and specialized compounding sources. Patients should consult with qualified healthcare providers before considering any peptide therapy.
Statements on this page have not been evaluated by the FDA and are not intended to diagnose, treat, cure, or prevent any disease. Many peptides described here are not FDA approved for the uses discussed, and some cannot lawfully be compounded in the United States. Nothing on this page is medical advice or a recommendation for any individual. Whether any therapy is appropriate depends on your history, your laboratory results, and a clinical evaluation. Individual results vary. This page is published for education. Use of this site does not create a physician-patient relationship.